Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland.

Publication

Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland.

Journal Paper/Review - Dec 13, 2023

Thoueille Paul, Alves Saldanha Susana, Schaller Fabian, Choong Eva, Munting Aline, Cavassini Matthias, Braun Dominique, Günthard Huldyrich F, Kusejko Katharina, Surial Bernard, Furrer Hansjakob, Rauch Andri, Rougemont Mathieu, Ustero Pilar, Calmy Alexandra, Stoeckle Marcel, Marzolini Catia, Di Benedetto Caroline, Bernasconi Enos, Schmid Patrick, Piso Rein Jan, Andre Pascal, Girardin François R, Guidi Monia, Buclin Thierry, Decosterd Laurent Arthur, Swiss HIV Cohort Study SHCS

Citation

Thoueille P, Alves Saldanha S, Schaller F, Choong E, Munting A, Cavassini M, Braun D, Günthard H, Kusejko K, Surial B, Furrer H, Rauch A, Rougemont M, Ustero P, Calmy A, Stoeckle M, Marzolini C, Di Benedetto C, Bernasconi E, Schmid P, Piso R, Andre P, Girardin F, Guidi M, Buclin T, Decosterd L, Swiss HIV Cohort Study S. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland. Lancet Reg Health Eur 2023; 36:100793.

Type

Journal Paper/Review (English)

Journal

Lancet Reg Health Eur 2023; 36

Publication Date

Dec 13, 2023

Issn Electronic

2666-7762

Pages

100793

Brief description/objective

The efficacy and tolerability of long-acting cabotegravir and rilpivirine were demonstrated in Phase III trials. However, low concentrations combined with other risk factors have been associated with an increased risk of virologic failure. This study aims to verify whether drug concentrations measured in a real-world setting are consistent with those previously reported.